|
US2008207668A1
|
|
Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse
|
|
AU2007203485A1
|
|
A novel pharmaceutical compound containing Abacavir sulfate and methods of making and using same
|
|
WO2007030577A2
|
|
Prodrugs of t3 and t4 with enhanced bioavailability
|
|
CN101305099A
|
|
Prodrugs of T3 and T4 with enhanced bioavailability
|
|
CN101193650A
|
|
Abuse-resistant amphetamine prodrugs
|
|
US2007060500A1
|
|
Pharmaceutical compositions for prevention of overdose or abuse
|
|
ZA200510383B
|
|
Abuse resistant amphetamine compounds
|
|
WO2006050421A1
|
|
Prodrugs of ribavirin with improved hepatic delivery
|
|
US2005176644A1
|
|
Compounds and compositions for prevention of overdose of oxycodone
|
|
US2007066537A1
|
|
Compounds and compositions for prevention of overdose of oxycodone
|
|
US2005266070A1
|
|
Abuse-resistant hydrocodone compounds
|
|
US2005054561A1
|
|
Abuse-resistant amphetamine compounds
|
|
MXPA05012850A
|
|
Abuse resistant amphetamine compounds.
|
|
AU2003290613A1
|
|
Controlled absorption of mixed thyroyd hormone formulations
|
|
WO03072047A2
|
|
Idothyronine compositions
|
|
IL163666D0
|
|
Active agent delivery systems and methods for protecting and administering active agents
|
|
CA2477038A1
|
|
Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
|
|
AU2003210454A1
|
|
Dendritic encapsulation of active agents
|
|
US2004063628A1
|
|
Active agent delivery systems and methods for protecting and administering active agents
|
|
US2004087483A1
|
|
Iodothyronine compositions
|
